Plus Therapeutics, Inc. (PSTV) Research

Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.

Market snapshot

Symbol
PSTV
Price
$4.20
Day change
-2.55%
Market cap
$10.2M
P/E ratio
-2.34x
52-week range
2.9-23.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$25.00

Recent news

  • Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform

    Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending shares of the Nasdaq-listed company up 8.7% to $5.89 Thursday. CNSide Diagnostics' Houston-based clinical laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, and overall laboratory management.

  • Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform

    Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely...

Peer companies

  • AN2 Therapeutics, Inc. (ANTX)
  • Boundless Bio, Inc. (BOLD)
  • Intensity Therapeutics, Inc. (INTS)
  • Iterum Therapeutics plc (ITRM)
  • Jasper Therapeutics, Inc. (JSPR)
  • NextCure, Inc. (NXTC)
  • Pluri Inc. (PLUR)
  • Q32 Bio Inc. (QTTB)

Recent insider activity

  • van Es-Johansson An — A-Award (3686 shares) on 2026-05-14
  • van Es-Johansson An — A-Award (3686 shares) on 2026-05-14
  • Hawkins Richard J — A-Award (3686 shares) on 2026-05-14
  • Hawkins Richard J — A-Award (3686 shares) on 2026-05-14
  • Guse Kyle — A-Award (3686 shares) on 2026-05-14

Open Plus Therapeutics, Inc. (PSTV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.